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Abstract: Glaucoma care today is often simplified into all or nothing terms with the assumption that if the patient’s 
intraocular pressure (IOP) is above a certain level, glaucomatous disease will progress and when the IOP is lowered to 
below a threshold, no further progression will occur. This dogma is largely the result of limitations in the resolution of 
tools currently available to judge progression. Glaucoma is a neurodegenerative disease and, as with all degenerative 
diseases, progression continues to occur, albeit at slower rates, with appropriate treatment. In the future, as our tools to 
assess structural and functional optic nerve change become more precise, we will no longer think of glaucoma as being 
stable or progressive but rather speak in terms of rates of progression.  
  There was a time when primary open-angle glaucoma 
was considered a disease of increased intraocular pressure 
(IOP). If one’s IOP was above the 95
th percentile upper limit 
of normal, (21 mm Hg in several Caucasian populations 
throughout the world) one would make the diagnosis of 
glaucoma. If IOP was lowered in such a patient to less than 
21 mm Hg, the patient would then be considered to have 
controlled glaucoma. If the IOP remained greater than 21 
mm Hg despite treatment, one would expect the patient to 
get worse (i.e., show progressive visual deterioration). 
  Several large prevalence surveys of glaucoma showed us 
that the relationship between IOP and primary open-angle 
glaucoma was not so simple. One such study was the 
Baltimore Eye Survey, conducted in East Baltimore, MD in 
the neighborhoods adjacent to Johns Hopkins Hospital. This 
study of over 5,000 individuals showed that approximately 
half of all individuals found to have open-angle glaucoma 
had an initial IOP reading of less than 21 mm Hg [1, 2]. 
Even with three IOP readings, 20% of those with 
glaucomatous disease were found to not have a single 
reading above 21 mm Hg. Further studies in North America 
and other regions of the world confirmed that the IOP-
glaucomatous disease relationship is continuous with no 
arbitrary IOP cutoff below and above which one’s disease 
will be stable or progressive respectively [3-7]. One such 
study in a Japanese population showed that even the 95
th 
percentile upper limit of IOP is not consistent across 
populations [4]. Both normal and glaucomatous individuals 
in Japan have lower IOP’s, on average, than similarly normal 
and diseased individuals in the United States. 
  A series of multicenter randomized clinical trials 
conducted in North America and Europe over the past 20 
years have shed more light on the IOP-primary open-angle 
glaucoma relationship [8-11]. The target goals for IOP 
lowering have varied between these studies with most 
aiming for a percentage reduction in IOP from baseline and  
one, the Advanced Glaucoma Intervention Study, setting an 
arbitrary number (18 mm Hg) as the target for successful 
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therapy. Glaucoma practice has evolved to replace the global 
target of 21 mm Hg with individualized target goals for 
patients depending upon disease severity and risk factors for 
vision loss. Most acknowledge that these target goals can 
change depending upon numerous factors including disease 
course, life expectancy and risks and benefits of the various 
therapies needed to achieve these goals. 
  Nevertheless, the fundamental principle that glaucoma 
will progress if the IOP is above a certain level and stabilize 
if it is below that level remains pervasive in practice today. 
We live in a binary world when it comes to glaucoma 
assessment and decision making. When glaucoma 
practitioners discuss patients with each other today, the 
terms they use include “above target” and “below target” 
when it comes to IOP. With regard to functional and 
structural assessment of the optic nerve, the commonly used 
terms include “stable” versus “progressive”. The twenty first 
century glaucoma dogma of glaucoma assessment and 
management can be summed up by the following: if IOP is 
above a target, glaucoma will worsen and if it is below 
target, glaucoma progression will be halted. Post-hoc 
analyses from randomized clinical trials that had been 
designed to answer other issues have been created to support 
this dogma [8]. There are some who believe that IOP 
lowering alone can completely halt glaucoma progression. 
Given that primary open-angle glaucoma is a chronic multi-
factorial neurodegenerative disease, the proposal that it can 
completely be arrested simply by impacting one risk factor is 
surprising, to say the least. 
  One reason that the present day dogma exists 
undoubtedly relates to the limitations of the tools that we 
currently have to assess glaucomatous disease including 
progression. For example, there are some patients with 
primary open-angle glaucoma based upon serial optic nerve 
examination who continues to have “normal” tests of optic 
nerve function with white-on-white automated perimetry. 
With regard to progression, there are eyes that are losing 
ganglion cells and axons over periods of time during which 
there are no statistical changes noted on white-on-white 
perimetric testing. The reverse may be true as well. There are 
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reveal statistical change while vision continues to 
deteriorate. The lack of resolution of the tools to confirm 
disease and disease progression in many circumstances when 
such disease and disease progression is present has 
significantly contributed to the binary glaucoma world in 
which we currently live. 
  Another enabling factor for this binary dogma may exist 
is that it simplifies the physician-patient encounter. It allows 
one to quickly reassure patients who have IOPs below target 
and are not showing progression while increasing therapy in 
those where IOP is above target or structural and/or 
functional optic nerve change has been noted. 
  The tools we possess for assessing structural and 
functional damage related to glaucoma including progression 
will improve dramatically in the coming years. In the not too 
distant future, a practitioner will be able to assess the number 
and function of living retinal ganglion cells in the clinic 
setting. Imaging devices will improve in resolution such that 
rates of change will be more precise. Perimetric testing will 
be able to pick up smaller increments of change. All of these 
advances will revolutionize how we view glaucoma as a 
disease. Most notably, we will do away with the binary 
dogma that has plagued glaucoma care for the past century. 
We will correctly recognize that glaucoma, like all chronic 
diseases, cannot be halted, and only slowed. It is well known 
that aging has been estimated to result in loss of 
approximately 5,000-10,000 retinal ganglion cells per year 
[12]. Other non IOP related risk factors will undoubtedly 
also be found to be important. 
  The major impact of such improved resolution of 
diagnostic tools for glaucoma care will be the focus on rates 
rather than on binary outcomes. It will be acknowledged that 
everyone is getting worse, some faster than others. It will not 
be sufficient to tell patients that their IOP is below target and 
thus they are not progressing or that additional therapy is 
necessary to lower IOP until they reach a lower level where 
they will no longer show such progression. When rates of 
change become readily available, this information will be 
shared with patients such that they better understand the 
pathophysiology and natural history of their glaucomatous 
disease. 
  The irony in all of the advances that are to come is that 
they will do more to remind us that glaucoma care is art 
rather than making treatment more scientific. Therapy will 
not be advanced because a patient shows statistical 
progression on a visual field test but rather because the rates 
of progression are deemed unacceptable given the patient’s 
severity of disease, overall health, age, risks and benefits of 
various treatment options and patient willingness to accept 
these risk-benefits trades-off. Unlike care in the present era 
of binary dogma, not all progression will have to be met with 
additional treatment because all patients will be deemed to 
be continually progressing, albeit at different rates. 
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